---
title: "Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292804824.md"
description: "Fractyl Health (NASDAQ: GUTS) reported one-year REMAIN-1 data showing its investigational Revita DMR System reduced weight regain by ~40% compared to sham after stopping GLP-1 therapy. The treatment demonstrated favorable safety with no serious device-related adverse events. Following the positive clinical results, Fractyl Health shares surged nearly 20%."
datetime: "2026-07-15T18:22:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292804824.md)
  - [en](https://longbridge.com/en/news/292804824.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292804824.md)
generator: "portal-rs"
---

# Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars

**Fractyl Health Inc.** (NASDAQ:GUTS) reported Wednesday one-year results from the Midpoint Cohort of its REMAIN-1 study, saying a single treatment with its investigational Revita DMR System helped patients maintain more of their GLP-1-induced weight loss than a sham procedure.

The clinical-stage metabolic therapeutics company said the latest findings reinforce Revita’s potential as a durable procedural therapy for weight maintenance after discontinuing GLP-1 treatment.

 **Read Also: Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product** 

## Revita Demonstrates Durable Weight Maintenance

In the modified intention-to-treat population of 45 participants, Revita reduced weight regain by about 40% versus the sham procedure after one year.

Patients treated with Revita experienced a least-squares mean weight regain of 7.8% of body weight compared with 13.0% in the sham group.

The company said patients who underwent more extensive duodenal ablation, defined as treatment exceeding 14 centimeters, retained about 81% of their GLP-1-induced weight loss after one year.

By comparison, participants in the sham arm maintained 48% of their weight loss.

Weight regain in this subgroup was 4.8% versus 13.0% in the sham arm, representing a reduction of more than 60%.

## Greater Benefit Seen In Higher-Risk Patients

The company also highlighted results from an optimized subgroup consisting of patients who received complete duodenal ablation and had achieved at least 17.5% weight loss during the GLP-1 run-in period.

In that group, Revita preserved approximately 84% of GLP-1-induced weight loss at one year, compared with 46% in the sham arm. Least-squares mean weight regain was 4.1% for Revita recipients versus 13.5% for sham-treated participants.

According to Fractyl, the findings suggest patients with a greater likelihood of regaining weight after stopping GLP-1 therapy may derive the greatest benefit from Revita.

## Responder Rate And Safety Profile

The company said 73% of patients in the Midpoint Cohort’s modified intention-to-treat population met the weight-maintenance responder threshold, which measures the proportion of patients maintaining at least 5% total body weight loss relative to their pre-tirzepatide weight after one year.

Among participants receiving complete duodenal ablation, the responder rate increased to 91%.

Fractyl also reported no device- or procedure-related serious adverse events during the study. No new device-related treatment-emergent adverse events were recorded between six and 12 months.

Overall treatment-emergent adverse event rates remained comparable between the Revita and sham groups at 24% and 25%, respectively.

The company added that one participant in the sham arm received a new diagnosis of Type 2 diabetes, while no new cases were reported among Revita-treated patients.

**GUTS Price Action:** Fractyl Health shares were up 19.54% at $0.85 at the time of publication on Wednesday, according to Benzinga Pro data.

 **Read Also: PayPal Stock Surges Nearly 15% in Premarket as Stripe and Advent International Reportedly Propose $53 Billion Joint Acquisition** 

*Image via Shutterstock*

### Related Stocks

- [GUTS.US](https://longbridge.com/en/quote/GUTS.US.md)
- [PYPL.US](https://longbridge.com/en/quote/PYPL.US.md)

## Related News & Research

- [Fractyl Health Earnings Call Signals Promise Amid Risks](https://longbridge.com/en/news/296690642.md)
- [Fractyl Health spotlights REMAIN-1 data showing Revita maintains 84% of GLP-1 weight loss in optimized cohort](https://longbridge.com/en/news/296481537.md)
- [AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial](https://longbridge.com/en/news/296265581.md)
- [Fractyl Health to host virtual Commercial Strategy Day on Revita go-to-market plan](https://longbridge.com/en/news/296479388.md)
- [GUTS: Revita enabled up to 84% weight loss retention one year after GLP-1 discontinuation](https://longbridge.com/en/news/292748479.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**